BUZZ-Australia's Clarity Pharma surges as US FDA approves trial
Reuters
Dec 22, 2025
BUZZ-Australia's Clarity Pharma surges as US FDA approves trial
** Shares of Australia's Clarity PharmaceuticalsCU6.AX rise as much as 11.4% to A$3.72, their highest since November 25
** Clinical stage radiopharma firm says it will commence a phase III trial of Cu-64 Sartate in patients with neuroendocrine tumours
** Co says to commence trial after a successful end of phase meeting with U.S. FDA in which all key components of proposed trial design were agreed upon with the agency
** CU6 down 14.4% YTD
(Reporting by Keshav Singh Chundawat in Bengaluru)
((Keshav.singhchundawat@thomsonreuters.com))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.